Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Drug ID: DCL000226

Drug Information
IndicationAcute or Chronic Pain
[ICD9: 338,780   ICD10: R52, G89]
Phase Ib    [1]
Rheumatoid ArthritisPhase IIa completed    [1]

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
Canonical SMILESCC(C)(C)C1=C(C=CC(=C1)O)O.C1=CC=C(C(=C1)C(=O)[O-])[O-].O.[Bi+2]    
Therapeutic ClassAnalgesics
CAS NumberCAS 750646-72-1
PubChem Compound IDCID 24759807.
TargetMAP kinase p38Inhibitor[2][3][4]
Ref 1Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. To Reference
Ref 2Investigations of SCIO-469-like compounds for the inhibition of p38 MAP kinase. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1461-4. Epub 2009 Jan 14. To Reference
Ref 3p38alpha-selective MAP kinase inhibitor reduces tumor growth in mouse xenograft models of multiple myeloma. Anticancer Res. 2008 Nov-Dec;28(6A):3827-33. To Reference
Ref 4Analgesic effects of p38 kinase inhibitor treatment on bone fracture healing. Pain. 2009 Mar;142(1-2):116-26. Epub 2009 Jan 23. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links


Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543